Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this randomized clinical trial, researchers reported that both topical and systemic finasteride treatments were similarly effective in increasing hair counts and terminal hair in men with androgenic alopecia after more than 3 months of follow-up.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

This study found that topical finasteride and flutamide both significantly reduced sebaceous gland growth and decreased prostatic weights in hamsters, indicating systemic effects despite local application.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

In testosterone-induced AGA mouse models, this study found that a dual-drug-loaded cationic nanoemulsion of minoxidil and finasteride enhanced follicle-associated retention, supporting hair regeneration while reducing systemic absorption and showing good skin compatibility, indicating a promising approach for androgenetic alopecia treatment.

In this study, finasteride improved cardiac sympathovagal balance in aging and obese male rats, also enhancing left ventricular function specifically in those modeled for aging, but not affecting healthy rats.

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

In this review, researchers explored the potential of topical finasteride as an innovative treatment for male pattern hair loss, addressing the limitations of oral finasteride, such as side effects and inconsistent effectiveness.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This study used computer simulations to evaluate the absorption of oral and topical finasteride for treating androgenetic alopecia, finding that topical applications resulted in lower plasma concentrations, suggesting potential viability as a treatment option.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

In this case study, a patient with long-standing androgenic alopecia and lupus showed a satisfactory response to treatment with oral and topical minoxidil after suboptimal outcomes with previous treatments.

In this study, a systematic review found that for androgenetic alopecia, systemic treatments like finasteride, dutasteride, and oral minoxidil are effective at slowing progression and promoting hair regrowth, with additional antiandrogen therapy options for women.

This study found that the HPCH-based formulation P-08–016 may facilitate finasteride deposition in the dermis, potentially offering an alternative to systemic therapy by minimizing systemic absorption.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

This study validated the differential stripping technique on hairless rat skin and found that the P-08–016 formulation delivered more finasteride to the epidermis and appendages compared to P-10–008.

No results are reported in this piece; it is a correspondence comment on treating hidradenitis suppurativa in children with finasteride.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

In this study, PRP combined with systemic therapy for androgenetic alopecia showed higher, but not statistically significant, improvements in hair density and width compared to PRP alone, with no increase in side effects; further prospective studies are recommended.

This study found that androgenetic alopecia patients treated with a combination of PRP and systemic therapy experienced greater but non-significant improvements in hair density and width compared to PRP monotherapy, without additional adverse effects, suggesting potential benefits for further exploration of combination regimens.

This study found that combining platelet-rich plasma with systemic therapies for androgenetic alopecia may result in greater improvements in hair density and width than using PRP alone, though the differences were not statistically significant.

In this article, researchers explored the potential of lipidic nanocarriers to enhance the delivery and effectiveness of finasteride in a topical gel form for androgenic alopecia, aiming to improve treatment options and reduce systemic adverse effects.

In this rodent study, researchers found that the drug finasteride may reduce anxiety and depression-like behaviors in a model of aging, despite inducing metabolic disturbances and depressive-like behaviors in young rats, suggesting potential considerations for its use in elderly populations.

This study found that topical finasteride was absorbed into the bloodstream to a minimal extent in male rats, even with repeated applications, suggesting low systemic exposure.

Finasteride effectively treated hidradenitis suppurativa.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

Taking finasteride daily can effectively and safely increase hair density and thickness for women with hair loss.